European Union - Czech - EMA (European Medicines Agency)

sandoz gmbh - epoetinum alfa - anemia; kidney failure, chronic - antianemické přípravky - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. kardiovaskulární stav, pre-existující anemie při zahájení chemoterapie).

European Union - Czech - EMA (European Medicines Agency)

mylan pharmaceuticals limited - emtricitabin, tenofovir-disoproxyl-maleinát - hiv infekce - antivirotika pro systémové použití - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 a 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 a 5.

European Union - Czech - EMA (European Medicines Agency)

hexal ag - epoetinum alfa - anemia; kidney failure, chronic; cancer - antianemické přípravky - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. léčba anémie a snížení počtu podání krevní transfúze u dospělých pacientů podstupujících chemoterapii pro solidní nádory, maligní lymfom nebo mnohočetný myelom, a na riziko transfuze, jak je hodnotí pacienta, celkový stav (e. kardiovaskulární stav, pre-existující anemie při zahájení chemoterapie).

European Union - Czech - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika pro systémové použití - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

European Union - Czech - EMA (European Medicines Agency)

zoetis belgium sa - maleát oktakitinibu - přípravky proti dermatitidě, kromě kortikosteroidů - psi - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

European Union - Czech - EMA (European Medicines Agency)

roche registration gmbh - metoxy-polyetylenglykol-epoetin beta - anemia; kidney failure, chronic - antianemické přípravky - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.

European Union - Czech - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabin, tenofovir-disoproxil-fumarát - hiv infekce - antivirotika pro systémové použití - treatment of hiv-1 infection: , truvada is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults. přípravek truvada je také indikován pro léčbu hiv-1 infikovaných mladistvých, s nrti odpor nebo toxicity smyslu, že brání použití první linii agentů, ve věku 12 až < 18 let. , pre-exposure prophylaxis (prep): , truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk.

European Union - Czech - EMA (European Medicines Agency)

teva b.v. - kyselina zoledronová - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - léky na léčbu nemocí kostí - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. léčba pagetovy choroby kostí u dospělých.

European Union - Czech - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

European Union - Czech - EMA (European Medicines Agency)

pfizer europe ma eeig  - tanezumab - osteoarthritis; pain - analgetika - treatment of moderate to severe chronic pain associated with osteoarthritis (oa) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (nsaids) and/or any opioid is ineffective, not tolerated or inappropriate.